After being hired by the US government and commercial researchers to promote a new advanced study on COVID-19, iSpecimen shares soared 126 % from recent lows.
The research is looking at the virus's transmissibility, variants, consequences, and testing validity, according to the firm, which is an online marketplace for human biospecimens.
Since its IPO in June, iSpecimen's stock has been soaring at all-time highs.
"We embrace the challenge and are gratified that researchers are coming to us for the specific biospecimens they need from the types of patients they're focusing on," said Christopher Ianelli, Founder and CEO of iSpecimen.
iSpecimen isn't a novel concept in COVID-19 research and development. It has collaborated with a number of organizations on a variety of initiatives needing various COVID-19 samples, such as nose swabs, saliva, and blood products, over the last ten months.
It began submitting serum samples to the US Centers for Disease Control and Prevention shortly after the outbreak last year to aid researchers in monitoring antibody development.
Multiple additional groups have contacted the company about creating special COVID-19 collections, according to the company.